DiaSorin S.p.A.
DIA
Clasificación en acciones
#3798
DiaSorin S.p.A. engages in research and development, manufacture, and... DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Precio por acción
$88.31
Última sincronización: 2026-10-21
Capitalización bursátil
$4.37B
Cambio (1 día)
-6.35%
Cambio (1 año)
-2.42%
País
IT
Comercio DiaSorin S.p.A. (DIA)
Categoría
Healthcare
Ganancias de DiaSorin S.p.A. (DIA)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di DiaSorin S.p.A., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de DiaSorin S.p.A. desde 2026 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $7.61B | - |
US
|
|
| $4.76B | - |
US
|
|
| $-252.70M | - |
US
|
|
| - | - |
CN
|
|
| $1.66B | - |
US
|
